This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Huang, W.-X. Articles by Hillert, J. Search for Related Content PubMed PubMed Citation Articles by Huang, W.-X. Articles by Hillert, J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                   What's this?

Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis

Department of Neurology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden

Ping Huang

Department of Neurology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden

Jan Hillert

Department of Neurology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden

It is increasingly clear that the CD40 and CD40 ligand (CD40L) receptor-ligand pair mediates a crucial activation signal in both cell-mediated and humoral immune responses. Here, we detected mRNA levels of CD40 and CD40L in non-stimulated peripheral blood mononuclear cells in 46 patients with multiple sclerosis (MS) and 46 healthy controls by a competitive RT-PCR procedure allowing quantification without previous culture or antigenic stimulation. The levels of CD40 and CD40L mRNA were markedly increased in MS patients (P <0.0001) compared with healthy controls. There was no difference between clinical MS subgroups or stage of disease. Our findings indicate that, although MS is an organ specific disorder an increased signaling via the CD40 and CD40L pathway may be present at the systemic level. The nature of this upregulation, whether primary or secondary to the organ-specific autoimmune response, is yet to be determined. Since interference with CD40/CD40L is an effective way to interfere with autoimmune model diseases such as experimental autoimmune encephalomyelitis, it may be relevant to investigate further the role of these molecules in the pathogenesis of MS.

Key Words: multiple sclerosis • CD40 • CD40 ligand Reverse transcription polymerase chain reaction (RT-PCR)

Multiple Sclerosis, Vol. 6, No. 2, 61-65 (2000)
DOI: 10.1177/135245850000600201


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M Zabaleta, R Marino, J Borges, B Camargo, P Ordaz, J B De Sanctis, and N E Bianco Activity profile in multiple sclerosis: an integrative approach A preliminary report Multiple Sclerosis, August 1, 2002; 8(4): 343 - 349. [Abstract] [PDF]